Virtual Conference Day

July 28, 2020 | 7:30 am – 6:00 pm EST

7:30 am Online speed networking

Synopsis

Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking! There will be an introduction to the conference and the flow of the day by the conference host, Nicholas Longworth (Hanson Wade) at 7.55am EST.

8:00 am Opening Keynote Address: Chromatin-modifying and RNA-modifying Enzyme Inhibitors as Precision Cancer Therapeutics

  • Robert Copeland President, Chief Scientific Officer and Co-Founder , Accent Therapeutics

Synopsis

  • The history of epigenetics – from first wave to present day 
  • Benefits of RNA modifying enzymes as a target 
  • Precise combination therapeutics in cancer (including epigenetics) for patients in the future 

8:30 am Targeting cancer with first-in-class inhibitors of the RNA m6A methyltransferase METTL3

  • Mark Albertella Vice President, Translational Oncology, Storm Therapeutics

Synopsis

  • Introduction to RNA modifications, the role of METTL3 and the m6A modification on selected mRNA species
  • Overview of our drug discovery efforts to identify potent and selective inhibitors of METTL3
  • Characterisation of potent, selective, bioavailable inhibitors of METTL3 in biochemical, biophysical and cellular assays
  • Exploration of utility of METTL3 inhibitors in hematological and solid tumour cell lines
  • Demonstration of in vivo activity of METTL3 inhibitors in hematological and solid tumour models

9:00 am From Somatic Mutations to Chromatin Topology – Emerging Tools For Epigenetic Biomarker Discovery

Synopsis

  • Introduction to Omni-C, a single assay for SNP detection, SV mapping and
    chromatin 3-D landscape characterization
  • Insights into drug response by capturing the 3-D gene regulatory landscape
  • Chromatin topology improves cancer genome characterization
  • Enhancing bio-marker discoveries with genome topology

9:15 am Overcoming Therapy Resistance to Cancer Immune Therapy – The role of epigenetic modulators

Synopsis

  • Cancer immunophenotypes and immune escape mechanisms – how to address resistance to immune checkpoint therapy
  • Immunomodulatory features of epigenetic drugs – rationale selection of combinations, dose, and schedule
  • Case studies: i) Broad-spectrum HDAC inhibitor resminostat in combination with opsonizing antibodies in haematological cancer; ii) Class I HDAC inhibitor domatinostat in combination with checkpoint blockade – translation of preclinical findings into the clinic

9:45 am Modulation of the Lysine Specific Demethylase 1 with iadademstat and vafidemstat: Cancer, Cognition and Behavior

Synopsis

  • Inhibition of LSD1 by irreversible binding to the FAD cofactor
  • Iadademstat for treatment of AML and SCLC
  • Increased of neuronal plasticity and improvement of cognitive and behavioral functions by treatment with vafidemstat
  • Modulation of LSD1 activity as a personalized medicine strategy in CNS disease.

10:15 am Online speed networking

Synopsis

Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking!

10:45 am Epigenetic Dual Targeting Compounds: Together is Better

Synopsis

  • The design and biological validation of compounds able to simultaneously hit two epigenetic targets will be discussed with their effects in cancer diseases, in comparison with the single-target inhibitors.

11:15 am Automated High-throughput ChIP-seq Workflow using Covaris Adaptive Focused Acoustics® System for Accelerated Epigenetic Drug Screening

  • Alon Goren Assistant Professor, Department of Medicine, University of California San Diego

Synopsis

  • Streamlining and reduce workflow time using automated ChIP-seq with the Covaris Adaptive Focused Acoustics (AFA)
  • Evaluation of the AFA technology in a range of epitopes, including H3K4me3, H3K27me3, H3K27ac, RNA Pol-II, CTCF, and HNF4A in different cell lines.
  • How to utilize AFA-based ChIP-seq processes for rapid epigenetic drug screening and clinical diagnostics

11:30 am Targeting epigenetic adaptation in ovarian cancer

Synopsis

  • Improving treatment of ovarian cancer is a major clinical unmet need.
  • Epigenetic adaptation is a driver of drug resistance in ovarian cancer.
  • Potential of histone methyltransferases to overcome drug resistance.
  • Modulation of the immune microenvironment by histone methyltransferases.

11:50 am The use of epigenetic therapy to improve the efficacy of immune checkpoint therapy for multiple common cancer types

12:10 pm Online Speed Networking & Midday Break

Synopsis

Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking!

12:30 pm Panel: Combination Therapies vs Monotherapies – Approaches with epigenetic therapies

Synopsis

  • Can HDAC inhibitors really work as a monotherapy?
  • Clinical trial implications of combination therapies

1:00 pm Panel: Our Social Media Feeds Are Personalized – Why Isn’t Our Medical Treatment?

Synopsis

  • The journey to personalized medicine and the role epigenetics will play 
  • How to design a drug development pipeline for precision medicine 
  • The future of personalised medicine – a pipe dream or legitimate goal? 

1:30 pm Online speed networking

Synopsis

Automated online speed networking – randomized matches made automatically based on profile – 5 rounds of 3 mins – to help people “accidentally meet”.

2:15 pm Panel: Toxicity and Off-Target Effects

  • Neil Michaud Senior Director, Translational Medicine, Epizyme
  • Paul Kayne Former Head, Discovery Genomics & Proteomics, Bristol-Myers Squibb
  • Kai He Assistant Professor of Medicine The Ohio State, University College of Medicine
  • Tamara Maes CSO, VP and founder, Oryzon Genomics

Synopsis

  • Overcoming the obstacles of toxicity regardless of target 
  • Techniques for monitoring toxicity and balancing this with efficacy 
  • Debating the dangers of off-target effects versus on-target effects 

2:45 pm Case Study: The Tazemetostat Story

  • Neil Michaud Senior Director, Translational Medicine, Epizyme

Synopsis

  • Designing a successful clinical trial – balancing efficacy and safety
  • Patient cohorts based on a diagnostic tool that identifies patients with specific EZH2 mutations
  • Future implications, plans and the move towards precision medicine in oncology

3:15 pm Selective Bromodomain Inhibition with the Bromodomain and Extraterminal Domain Inhibitor Apabetalone: Discovery to Phase 3 Cardiovascular Outcomes Study

Synopsis

  • Epigenetic regulation and BET system in CVD/T2DM
  • Mechanism of Apabetalone
  • Highlights of Pre-clinical and Clinical Data

3:45 pm Targeting SMARCA4-mutant lung cancers through selective, chemically-induced degradation of SMARCA2

  • Robert Yauch Director & Principal Scientist, Discovery Oncology, Genentech

Synopsis

  • SMARCA4 is mutationally-inactivated in subsets of lung cancer leading to a dependency on the paralog helicase, SMARCA2
  • The discovery and development of selective SMARCA2 inhibitors would be essential for therapeutically targeting SMARCA4-mutant lung cancers
  • In vitro characterization and demonstration of in vivo activity of potent and selective degraders of SMARCA2

4:15 pm Targeting cancer therapy with an epigenetic drug: Pre-clinical and clinical experience

  • Richard Trauger Senior Director Translational Medicine, Viracta Therapeutics

Synopsis

  • Specificity and properties of a compound in relation to clinical application
  • Creating an oral drug and a dosing schedule that works
  • Virus activation vs HDAC inhibitors

4:45 pm Online Networking break

Synopsis

Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking!

5:00 pm Design of combination strategies and identification of biomarkers associated with clinical response to the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients

  • Eric Campeau Senior Director, Translational Medicine, Zenith Epigenetics

Synopsis

  • Optimal combination agents to use with BET bromodomain inhibitors in the clinic
  • Patient populations that can benefit from combinatorial therapies with ZEN-3694
  • Biomarkers of response of ZEN-3694 + enzalutamide in mCRPC patients

5:20 pm The antileukemic effect exerted by LSD1 inhibition

5:40 pm Panel: The Role of Epigenetics in an Oncology Portfolio

  • Mahesh Karande President and CEO, Omega Therapeutics
  • Susan Wee Senior Director, Oncology Drug Discovery, Incyte
  • Eric Campeau Senior Director, Translational Medicine, Zenith Epigenetics
  • Hugh Young Reinhoff, CEO, Imago BioSciences

Synopsis

  • Utilizing epigenetics in combination with immunotherapies to further bolster the immune response
  • Building a differentiated oncology portfolio based on standalone epigenetic (mono)therapies
  • Imagining the future of epigenetic therapies in oncology and beyond

6:30 pm Closing remarks and end of virtual conference